Wegovy and Zepbound are separate prescription brands used in U.S. weight-management care, but they contain different active ingredients. Wegovy products contain semaglutide, while Zepbound contains tirzepatide. Their mechanisms, labeled populations, available forms and clinical evidence must be compared using the exact products studied—not a broad slogan that one GLP-1 drug is always better.
There is a particularly useful direct study: SURMOUNT-5 compared specified weekly injections of tirzepatide and semaglutide in adults with obesity without diabetes for 72 weeks. Its results inform this brand comparison, but do not directly compare Wegovy oral tablets or Wegovy HD against Zepbound, nor predict what every patient will experience.
A practical decision also depends on contraindications, injection or oral routines, insurance authorization, prescription fulfillment and possible additional labeled indications. This guide covers those clinical and product distinctions; monthly prices and manufacturer discounts belong to a separate financial comparison.
Wegovy is the semaglutide brand family, including a conventional injection, tablets and an HD injectable presentation. Zepbound is tirzepatide, a dual GIP/GLP-1 receptor agonist. Product labels, devices and prescribing indications are not interchangeable.
A comparison must establish the exact brand and formulation first. Review Wegovy product forms and the distinct semaglutide–tirzepatide ingredient comparison before interpreting a broad drug-class claim.
SURMOUNT-5 directly randomized 751 adults with obesity but without type 2 diabetes to maximum-tolerated weekly tirzepatide (10 or 15 mg) or weekly semaglutide (1.7 or 2.4 mg) injections. At 72 weeks the least-squares mean weight change was −20.2% with tirzepatide versus −13.7% with semaglutide. The trial therefore supports a comparison of those specified injectable regimens, not every newer Wegovy form.
This was an open-label trial funded by Lilly, with the usual limits of studied patients, treatment tolerance and protocol. It did not directly test oral Wegovy tablets or Wegovy HD 7.2 mg. Use the result to inform a clinician discussion about eligible injections rather than treating the numbers as guarantees for any individual or as dose-conversion instructions.
| Decision point | Wegovy | Zepbound |
|---|---|---|
| Active ingredient | Semaglutide | Tirzepatide |
| Receptor activity | GLP-1 | GIP and GLP-1 |
| Weight-management presentation | Weekly injections; separate oral and HD options | Branded injectable product with its own device instructions |
| Direct obesity evidence | SURMOUNT-5 weekly injectable arm | SURMOUNT-5 weekly injectable arm |
| Additional labeled uses | Verify each Wegovy presentation | Includes qualifying adult OSA indication |
| Route to access | Exact Wegovy product and valid prescription | Exact Zepbound product and valid prescription |
Both brands have FDA-approved obesity/weight-management uses for specified eligible populations. Some presentations have additional labeled indications: Zepbound has an approval for moderate-to-severe obstructive sleep apnea in adults with obesity, while certain Wegovy injections have separate risk-reduction or other indications.
These additional authorizations should not be assumed for every formulation or patient. A pharmacy sale does not determine eligibility; the clinician must match the exact indication and form to the individual’s clinical circumstances.
SURMOUNT-5 was an open-label randomized trial of 751 adults with obesity but without diabetes. It compared maximum tolerated weekly tirzepatide 10 or 15 mg against weekly semaglutide 1.7 or 2.4 mg, with diet and exercise counseling.
At 72 weeks, least-squares mean weight change was −20.2% with tirzepatide versus −13.7% with semaglutide (P<0.001). These are group averages from particular injected regimens, not guaranteed personal outcomes or comparative estimates for newer tablet or Wegovy HD products.
Gastrointestinal symptoms occurred in both SURMOUNT-5 study groups, especially during escalation. Separately, FDA labels describe boxed thyroid C-cell tumor warnings and other important risks for both products.
A single side-effect percentage from one study is not a complete safety ranking. A prescribing clinician must consider contraindications, co-medications, medical history and product-specific warnings.
The weekly semaglutide injections evaluated in SURMOUNT-5 do not create head-to-head evidence for Wegovy tablets or the separately approved Wegovy HD 7.2-mg presentation. Tablet administration instructions and injection devices are not reducible to one generic Wegovy schedule.
If a buyer wants pills rather than injections, the useful alternative comparison is Wegovy pill vs Foundayo. Comparing a tablet to the injectable Zepbound brand should not import SURMOUNT-5 conclusions without qualification.
Trial superiority for a study endpoint does not override clinical contraindications, indication restrictions or the patient’s prior tolerability. It also does not tell the pharmacist how to convert doses or substitute prescriptions across brands.
Treatment changes require a prescriber’s assessment and appropriate order. Purchasing both, or following a weight-loss table to self-adjust dosing, is not a safe interpretation of clinical evidence.
The central evidence question is whether the proposed Wegovy form is actually the weekly injection used in SURMOUNT-5. A prescription for Wegovy tablets or HD changes that evidence match. A proposed Zepbound regimen also requires its exact indication and presentation, not an extrapolation from the brand name alone.
After identifying the product, review tolerability, clinical history, additional labeled uses and the member’s coverage. For example, Zepbound has a separate obstructive sleep apnea indication in eligible adults with obesity; it is not an automatic claim for every person comparing weight-loss therapy.
A shopper may read a SURMOUNT-5 headline and then find a Wegovy tablet offer. That study assessed weekly injections, so its headline weight differences do not independently evaluate the pill. The Wegovy tablet profile identifies the oral product, while Wegovy HD separately covers the high-dose injection with its own labeling.
Use the form on the prescription as the unit of decision. If the clinician is comparing weekly injectable regimens, the head-to-head evidence is directly relevant within its trial limitations; if the clinician is considering tablets or a distinct HD indication, an entirely different evidence and label review is needed.
If a clinician considers either of the studied weekly injections, the published head-to-head trial can contribute evidence about average weight reduction. The prescriber must still assess contraindications, side effects, treatment goals and which exact branded medication and device are suitable. A higher group mean does not settle the full clinical decision.
For legal fulfillment steps, use Zepbound acquisition or Wegovy acquisition. The prescribed product cannot be replaced with another molecule or with oral Wegovy solely because a pharmacy shows a different offer.
Zepbound has different labeled injectable presentations, and the pharmacy should match the specific device or vial configuration on the prescription. Wegovy may be an injection or a tablet, and Wegovy HD is separately identified. A comparison advertisement that says only “four doses of weight-loss injection” does not identify either exact product.
Confirm the U.S. dispenser, valid prescription and exact package. If a telehealth service uses a fulfillment partner, ask for the pharmacy’s legal identity before paying. Neither a published clinical study nor a marketing affiliation proves that a retailer has stock.
An insurer can review Wegovy and Zepbound against separate indication and prior-authorization criteria. Their manufacturer offers also differ by product, presentation and eligibility; a Zepbound vial quote is not directly comparable to a Wegovy pen promotional rate.
The dedicated Wegovy–Zepbound cost comparison handles matched supply and payment rules. Keep this clinical article centered on the trial and its limits, not a cost-per-milligram calculation between different molecules.
The clinical evidence here is restricted to named studies and current labeled uses; no cross-trial or cross-form dose equivalence is asserted.
Some links may lead to compensated commercial referrals. No referral arrangement establishes medical suitability or substitutes for clinician judgment.
No. Zepbound contains tirzepatide; Wegovy contains semaglutide.
A direct trial compared specified weekly semaglutide and tirzepatide injection regimens in adults with obesity without diabetes.
At 72 weeks, mean weight reductions were 13.7% for studied semaglutide injections and 20.2% for tirzepatide injections.
No. The results relate to the studied weekly injections, not Wegovy tablets.
No. The study regimen should not be generalized to that distinct higher-dose presentation.
Yes. Each requires appropriate clinical prescribing and lawful pharmacy dispensing.
It has a specific FDA-labeled use for moderate-to-severe obstructive sleep apnea in adults with obesity.
They are different active ingredients and not automatic pharmacy substitutes.
Not necessarily. Costs depend on product, quantity, insurance and applicable manufacturer terms.